The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis

Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis

August 9, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Mesoblast Ltd. on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

You Might Also Like
  • Atacicept Shows Promise in Lupus Treatment Trials
  • J&J’s Stelara Shows Promise Against Lupus in Study
  • Sifalimumab Shows Some Promise Against Lupus

Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with no serious side effects or infusion-related adverse events in the 48-patient, 12-week Phase II study, the company says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Among patients previously treated with at least one biologic drug, the common measure of 20% relief of signs and symptoms of the arthritis, known as ACR20, was achieved by 55% of those who received an infusion of 2 million cells per kilogram of weight. That compared with 33% in the placebo group who achieved ACR20.

The higher bar of ACR70, or 70% improvement, was achieved by 36% after one infusion of the Mesoblast treatment, compared with no patients in the placebo group who reported such an improvement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The cell treatment also led to improvements in measures of physical function and overall disease activity versus placebo, the company said.

“The safety and efficacy results of this study are very encouraging and suggest that Mesoblast’s cell therapy has the potential to fill the major unmet medical need” for patients who cannot take biologic treatments, Dr. Allan Gibofsky, rheumatologist at Hospital for Special Surgery in New York, says in a statement.

Mesoblast, which is 14.6% owned by Teva Pharmaceutical Industries, says it plans to line up a partner to help it move the treatment into larger Phase III trials.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

About one third of patients either do not respond sufficiently or cannot tolerate popular biologic treatments for rheumatoid arthritis, such as adalimumab, the world’s top-selling prescription medicine, creating a need for new therapy options.

To be competitive with current medicines, new treatments must address both pain and disease progression.

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: mesenchymal precursor cell, Rheumatoid Arthritis (RA), stem cell therapy, Stem Cells

You Might Also Like:
  • Atacicept Shows Promise in Lupus Treatment Trials
  • J&J’s Stelara Shows Promise Against Lupus in Study
  • Sifalimumab Shows Some Promise Against Lupus
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)